ATE166867T1 - Azacyclische verbindungen, sie enthaltende zusammensetzungen und ihre verwendung als tachykinin antagoniste - Google Patents
Azacyclische verbindungen, sie enthaltende zusammensetzungen und ihre verwendung als tachykinin antagonisteInfo
- Publication number
- ATE166867T1 ATE166867T1 AT94907565T AT94907565T ATE166867T1 AT E166867 T1 ATE166867 T1 AT E166867T1 AT 94907565 T AT94907565 T AT 94907565T AT 94907565 T AT94907565 T AT 94907565T AT E166867 T1 ATE166867 T1 AT E166867T1
- Authority
- AT
- Austria
- Prior art keywords
- optionally substituted
- 6alkyl
- pct
- compounds
- tachykin
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 150000004030 azacyclic compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 2
- 241000689227 Cora <basidiomycete fungus> Species 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 102000003141 Tachykinin Human genes 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 108060008037 tachykinin Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939303243A GB9303243D0 (en) | 1993-02-18 | 1993-02-18 | Therapeutic agents |
| GB939322150A GB9322150D0 (en) | 1993-10-27 | 1993-10-27 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE166867T1 true ATE166867T1 (de) | 1998-06-15 |
Family
ID=26302480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94907565T ATE166867T1 (de) | 1993-02-18 | 1994-02-10 | Azacyclische verbindungen, sie enthaltende zusammensetzungen und ihre verwendung als tachykinin antagoniste |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5633266A (de) |
| EP (1) | EP0683767B1 (de) |
| JP (1) | JPH08506823A (de) |
| AT (1) | ATE166867T1 (de) |
| AU (1) | AU679207B2 (de) |
| CA (1) | CA2152925A1 (de) |
| DE (1) | DE69410784T2 (de) |
| ES (1) | ES2116583T3 (de) |
| WO (1) | WO1994019323A1 (de) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL111960A (en) * | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| CA2180746A1 (en) * | 1994-01-13 | 1995-07-20 | Raymond Baker | Gem-disubstituted azacyclic tachykinin antagonists |
| GB9402688D0 (en) * | 1994-02-11 | 1994-04-06 | Merck Sharp & Dohme | Therapeutic agents |
| US5747491A (en) * | 1994-05-05 | 1998-05-05 | Merck Sharp & Dohme Ltd. | Morpholine derivatives and their use as antagonists of tachikinins |
| DE19504627A1 (de) * | 1995-02-13 | 1996-08-14 | Bayer Ag | Verfahren und neue Zwischenprodukte zur Herstellung von Triazolinonen |
| GB9513117D0 (en) * | 1995-06-28 | 1995-08-30 | Merck Sharp & Dohme | Therapeutic agents |
| GB9513121D0 (en) * | 1995-06-28 | 1995-08-30 | Merck Sharp & Dohme | Therapeutic agents |
| US6013631A (en) | 1998-06-19 | 2000-01-11 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) deletion analogs |
| AU7552401A (en) * | 2000-06-12 | 2001-12-24 | Univ Rochester | Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist |
| US7407480B2 (en) * | 2001-07-27 | 2008-08-05 | Ams Research Corporation | Method and apparatus for correction of urinary and gynecological pathologies, including treatment of incontinence cystocele |
| US20060205724A1 (en) * | 2002-05-29 | 2006-09-14 | The Regents Of The University Of California | Antagonizing nk-1 receptors inhibits consumption of substances of abuse |
| CA2573271C (en) | 2004-07-15 | 2015-10-06 | Amr Technology, Inc. | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| EP1790636A4 (de) * | 2004-09-17 | 2009-07-01 | Takeda Pharmaceutical | Piperidinderivate und deren anwendung |
| WO2006115285A1 (ja) * | 2005-04-21 | 2006-11-02 | Takeda Pharmaceutical Company Limited | 医薬組成物 |
| WO2006123182A2 (en) | 2005-05-17 | 2006-11-23 | Merck Sharp & Dohme Limited | Cyclohexyl sulphones for treatment of cancer |
| BRPI0613403A2 (pt) | 2005-07-15 | 2009-02-10 | Amr Technology Inc | tetrahidrobenzodiazepinas aril- e heteroarila-substituÍdas e uso das mesmas para bloquear a recaptaÇço de norepinefrina, dopamina e serotonina |
| JP4879988B2 (ja) | 2005-09-29 | 2012-02-22 | メルク・シャープ・エンド・ドーム・コーポレイション | メラノコルチン−４受容体モジュレーターとしてのアシル化スピロピペリジン誘導体 |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| EP2083831B1 (de) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Verfahren zur behandlung von fettsäure-synthese-hemmern |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| EP2336120B1 (de) | 2007-01-10 | 2014-07-16 | MSD Italia S.r.l. | Kombinationspräparate enthaltend amidsubstituierte Indazole als Poly-(ADP-ribose)-Polymerase (PARP)-Hemmer |
| EP2145884B1 (de) | 2007-04-02 | 2014-08-06 | Msd K.K. | Indoledionderivat |
| US8389553B2 (en) | 2007-06-27 | 2013-03-05 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| MX2010006045A (es) * | 2007-12-12 | 2010-06-23 | Amgen Inc | Inhibidores de transportador de glicina-1. |
| US8598184B2 (en) | 2008-03-03 | 2013-12-03 | Tiger Pharmatech | Protein kinase inhibitors |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| ES2662072T3 (es) | 2009-05-12 | 2018-04-05 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y uso de la misma |
| EP2429295B1 (de) | 2009-05-12 | 2013-12-25 | Albany Molecular Research, Inc. | Aryl-, heteroaryl- und heterocyclen-substituierte tetrahydroisochinoline und ihre verwendung |
| JP5739415B2 (ja) | 2009-05-12 | 2015-06-24 | ブリストル−マイヤーズ スクウィブ カンパニー | （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用 |
| KR101485645B1 (ko) | 2009-10-14 | 2015-01-22 | 머크 샤프 앤드 돔 코포레이션 | ｐ53 활성을 증가시키는 치환된 피페리딘 및 그의 용도 |
| US8999957B2 (en) | 2010-06-24 | 2015-04-07 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as ERK inhibitors |
| CN107090456B (zh) | 2010-08-02 | 2022-01-18 | 瑟纳治疗公司 | 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制 |
| EP4079856A1 (de) | 2010-08-17 | 2022-10-26 | Sirna Therapeutics, Inc. | Rna-interferenz-vermittelte hemmung der hepatitis b-virus (hbv)-genexpression mittels kurzer interferierender nukleinsäure (sina) |
| EP2608669B1 (de) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer |
| WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| EP2615916B1 (de) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Kondensierte pyrazolderivate als neue erk-hemmer |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| EP2654748B1 (de) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazolderivate als erk-hemmer |
| US20140045847A1 (en) | 2011-04-21 | 2014-02-13 | Piramal Enterprises Limited | Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| EP2770987B1 (de) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Neue verbindungen als erk-hemmer |
| EP2844261B1 (de) | 2012-05-02 | 2018-10-17 | Sirna Therapeutics, Inc. | Sina-zusammensetzungen |
| EP2900241B1 (de) | 2012-09-28 | 2018-08-08 | Merck Sharp & Dohme Corp. | Neuartige verbindungen als erk-hemmer |
| SI2925888T1 (en) | 2012-11-28 | 2018-02-28 | Merck Sharp & Dohme Corp. | Compounds and methods for the treatment of cancer |
| RU2690663C2 (ru) | 2012-12-20 | 2019-06-05 | Мерк Шарп И Доум Корп. | Замещенные имидазопиридины в качестве ингибиторов hdm2 |
| US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
| EP3041938A1 (de) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Kreisförmige polynukleotide |
| US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| EP3833668A4 (de) | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | Prmt5-inhibitoren |
| US11981701B2 (en) | 2018-08-07 | 2024-05-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6033439B2 (ja) * | 1980-03-07 | 1985-08-02 | 財団法人相模中央化学研究所 | ジペプチドの製造方法 |
| WO1991009844A1 (en) * | 1990-01-04 | 1991-07-11 | Pfizer Inc. | Substance p antagonists |
| ATE154354T1 (de) * | 1991-02-11 | 1997-06-15 | Merck Sharp & Dohme | Azabicyclische verbindungen, diese enthaltende pharmazeutische zubereitungen und ihre therapeutische verwendung |
| US5459270A (en) * | 1991-08-20 | 1995-10-17 | Merck Sharp & Dohme Limited | Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them |
| AU675786B2 (en) * | 1992-04-15 | 1997-02-20 | Merck Sharp & Dohme Limited | Azacyclic compounds |
| US5444074A (en) * | 1992-04-15 | 1995-08-22 | Merck Sharp & Dohme Limited | Piperidine tachykinin receptor antagonists |
| US5496833A (en) * | 1993-04-13 | 1996-03-05 | Merck Sharp & Dohme Limited | Piperidine tachykinin receptor antagonists |
-
1994
- 1994-02-10 DE DE69410784T patent/DE69410784T2/de not_active Expired - Fee Related
- 1994-02-10 CA CA002152925A patent/CA2152925A1/en not_active Abandoned
- 1994-02-10 AT AT94907565T patent/ATE166867T1/de not_active IP Right Cessation
- 1994-02-10 AU AU61093/94A patent/AU679207B2/en not_active Ceased
- 1994-02-10 EP EP94907565A patent/EP0683767B1/de not_active Expired - Lifetime
- 1994-02-10 WO PCT/EP1994/000412 patent/WO1994019323A1/en active IP Right Grant
- 1994-02-10 JP JP6518622A patent/JPH08506823A/ja not_active Ceased
- 1994-02-10 US US08/495,429 patent/US5633266A/en not_active Expired - Fee Related
- 1994-02-10 ES ES94907565T patent/ES2116583T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU6109394A (en) | 1994-09-14 |
| DE69410784D1 (de) | 1998-07-09 |
| JPH08506823A (ja) | 1996-07-23 |
| ES2116583T3 (es) | 1998-07-16 |
| US5633266A (en) | 1997-05-27 |
| WO1994019323A1 (en) | 1994-09-01 |
| CA2152925A1 (en) | 1994-09-01 |
| DE69410784T2 (de) | 1999-01-14 |
| AU679207B2 (en) | 1997-06-26 |
| EP0683767A1 (de) | 1995-11-29 |
| EP0683767B1 (de) | 1998-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE166867T1 (de) | Azacyclische verbindungen, sie enthaltende zusammensetzungen und ihre verwendung als tachykinin antagoniste | |
| ATE192737T1 (de) | Aralkoxy und aralkylthio substituierte azacyclische verbindungen als tachykinin antagonisten | |
| ES2141174T3 (es) | 4-arilmetiloximetil piperidinas como antagonistas de taquiquinina. | |
| EP0611301A4 (de) | Chelat-zubereitungen, die oximverbindungen enthalten. | |
| ATE127808T1 (de) | Atp-analogen. | |
| DE69116127D1 (de) | Piperazinderivate | |
| FR2673427B1 (fr) | Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant. | |
| MXPA02011418A (es) | 1-aminoalquil-lactamas sustituidas y su uso como antagonistas del receptor muscarinico. | |
| MY113945A (en) | Amino substituted pyrimidines and triazines | |
| ATE284692T1 (de) | Verwendung von nicht-peptidischen bradykinin- antagonisten zur herstellung von arzneimitteln zur behandlung und prävention der alzheimerischen krankheit | |
| ATE148741T1 (de) | Reinigendes desinfektionsmittel | |
| SE7710783L (sv) | Alfa-(4-bifenylyl)-bensyl-azolium-salter till anvendning for bekempning av mikroorganismer och sett att framstella foreningarna | |
| BR9508676A (pt) | Carbamolicarboxamida composição processos para preparar compostos e a composição e para controlar fungos nocivos e uso compost e das composições | |
| YU43902A (sh) | Novi razgranati supstituisani amino derivati od 3-amino-1- -fenil-1h(1,2,4) triazola, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže | |
| DE69029861D1 (de) | N-acyl-substituierte azazyklische verbindungen, verfahren zu deren herstellung und deren verwendung als arzneimittel | |
| PL316964A1 (en) | O-acyl 4-phenyl cyclohexanol, yheir salts, therapeutic agents containing such compound as well as their application and method of obtaining them | |
| DE59807744D1 (de) | Verwendung von sulfonyloxadiazolonen als mikrobizide | |
| TW372955B (en) | Substituted 1-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them | |
| HUP0003548A2 (hu) | Tachikinin receptor antagonista hatású 2-acilamino-propán-aminok és az ezeket tartalmazó gyógyszerkészítmények | |
| DE50001988D1 (de) | DOLLAR g(a)- DOLLAR g(a)' -SUBSTITUIERTE N-ALKYL-3-ALKENYLBENZOYL-PYRAZOL-DERIVATE | |
| FI803996L (fi) | 1-(2-propynyloxy)-2-amino-3-propanoletrar | |
| SE8205587D0 (sv) | 1,2,3-tiadiazol-5-yl-karbamid-derivat och sett att framstella dessa foreningar samt medel, innehallande foreningarna, med tillvextreglerande och avlovande verkan | |
| TH37500A (th) | อนุพันธ์ซิส-ซับสทิทิวเทด ซับสทิทิวเทด อะมิโนไซโคลแอลคิล พิร์โรลิอีน | |
| ATE116642T1 (de) | Interne salze des 2,4-diamino-6-alkoxy-3- sulphooxypyrmidium-hydroxids und ihre verwendung für die behandlung und die verhütung des haarausfalls. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |